secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-10-15T12:00:14+00:00
Accession:  0001683168-26-007857
Event type: other_material
Sentiment:  positive
Materiality: 0.32
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Valion Bio unit Velocity Bioworks completes initial feasibility test of LarmorBio BioScan-NMR platform
--------------------------------------------------------------------------------

- Initial evaluation found a strong correlation between BioScan-NMR signal and optical density at 600 nm (OD600), a common measure of cell density in liquid cultures.
- Milestone came less than six months after Valion Bio secured exclusive rights to LarmorBio's next-generation NMR technology.
- Platform is being developed as process analytical technology to track cell size, density, viability and phenotype inside bioreactors via continuous, non-invasive closed-system monitoring.
- Interim CEO Dean Zikria called it an 'early-stage proof-of-concept' with encouraging results; Velocity Bioworks will use the data to guide further development of continuous monitoring.
- Stated goals include earlier detection of process deviations, fewer batch failures and lower manufacturing costs; no financial terms, revenue or timelines disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826007857/0001683168-26-007857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826007857/valion_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer